SeQuent Scientific is currently trading at Rs. 143.90, up by 3.00 points or 2.13% from its previous closing of Rs. 140.90 on the BSE.
The scrip opened at Rs. 141.00 and has touched a high and low of Rs. 144.00 and Rs. 140.35 respectively. So far 1,543 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 260.00 on 22-Dec-2015 and a 52 week low of Rs. 124.00 on 03-Jun-2015.
Last one week high and low of the scrip stood at Rs. 145.30 and Rs. 132.90 respectively. The current market cap of the company is Rs. 3,428.00 crore.
The promoters holding in the company stood at 56.25% while Institutions and Non-Institutions held 21.32% and 22.43% respectively.
SeQuent Scientific’s subsidiary Alivira Animal Health (Alivira) has signed a definitive agreement to acquire majority stake in Karizoo Group, Spain, one of the leading animal health groups in Spain and European markets. The transaction is subject to customary closing conditions and is expected to close by July 2016.
Alivira would acquire 60% stake in the family held Vila Vina Particpacions (VVP) which owns Karizoo Spain, Phytosolutions Spain, Covivet Spain and Karizoo Mexico. The existing promoters will continue to hold the balance 40% stake. The acquisition will be made through Alivira Ireland, a wholly owned subsidiary of the company.
This acquisition makes Alivira a significant player in the Global Animal health space with annualized revenues in excess of $120 million. Alivira will now account for over 2/3rd of SeQuent revenues with formulations business accounting for over 75% of Alivira business.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: